LU92166I2 - Glycopyrronium ou un de ses sels - Google Patents

Glycopyrronium ou un de ses sels

Info

Publication number
LU92166I2
LU92166I2 LU92166C LU92166C LU92166I2 LU 92166 I2 LU92166 I2 LU 92166I2 LU 92166 C LU92166 C LU 92166C LU 92166 C LU92166 C LU 92166C LU 92166 I2 LU92166 I2 LU 92166I2
Authority
LU
Luxembourg
Prior art keywords
glycopyrrolate
dry powder
glycopyrronium
salt
formulation
Prior art date
Application number
LU92166C
Other languages
English (en)
Original Assignee
Sosei R & D Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9889490&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LU92166(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sosei R & D Ltd filed Critical Sosei R & D Ltd
Publication of LU92166I2 publication Critical patent/LU92166I2/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Otolaryngology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Detergent Compositions (AREA)
  • Saccharide Compounds (AREA)
  • Steroid Compounds (AREA)
LU92166C 2000-04-07 2013-03-13 Glycopyrronium ou un de ses sels LU92166I2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0008660.3A GB0008660D0 (en) 2000-04-07 2000-04-07 The treatment of respiratory diseases
PCT/GB2001/001606 WO2001076575A2 (fr) 2000-04-07 2001-04-09 Traitement de troubles respiratoires

Publications (1)

Publication Number Publication Date
LU92166I2 true LU92166I2 (fr) 2014-03-13

Family

ID=9889490

Family Applications (2)

Application Number Title Priority Date Filing Date
LU92166C LU92166I2 (fr) 2000-04-07 2013-03-13 Glycopyrronium ou un de ses sels
LU92393C LU92393I2 (fr) 2000-04-07 2014-03-07 Glycopyrronium ou un sel de celui-ci, plus particulièrement le sel bromure, combiné à indacatérol ouun sel de celui-ci, plus particulièrement le sel maléate

Family Applications After (1)

Application Number Title Priority Date Filing Date
LU92393C LU92393I2 (fr) 2000-04-07 2014-03-07 Glycopyrronium ou un sel de celui-ci, plus particulièrement le sel bromure, combiné à indacatérol ouun sel de celui-ci, plus particulièrement le sel maléate

Country Status (25)

Country Link
US (3) US7229607B2 (fr)
EP (3) EP1267866B2 (fr)
JP (1) JP5042426B2 (fr)
CN (3) CN1292745C (fr)
AT (1) ATE330585T2 (fr)
AU (2) AU2004242450B2 (fr)
BE (1) BE2013C023I2 (fr)
BR (1) BR0109875A (fr)
CA (1) CA2405705C (fr)
CY (1) CY1105120T1 (fr)
DE (1) DE60120936T3 (fr)
DK (1) DK1267866T4 (fr)
ES (2) ES2266242T5 (fr)
GB (1) GB0008660D0 (fr)
HK (1) HK1050846B (fr)
HU (2) HU230958B1 (fr)
IL (2) IL151791A0 (fr)
LU (2) LU92166I2 (fr)
MX (1) MXPA02009718A (fr)
NO (3) NO336142B1 (fr)
NZ (2) NZ535284A (fr)
PL (1) PL364024A1 (fr)
PT (1) PT1267866E (fr)
WO (1) WO2001076575A2 (fr)
ZA (1) ZA200207420B (fr)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0008660D0 (en) * 2000-04-07 2000-05-31 Arakis Ltd The treatment of respiratory diseases
PT1337239E (pt) 2000-11-30 2010-01-26 Vectura Ltd Partículas servindo à preparação de uma composição farmacêutica
PT2283818T (pt) 2000-11-30 2017-10-09 Vectura Ltd Método de preparação de partículas para utilização numa composição farmacêutica
US20050130990A1 (en) * 2001-03-23 2005-06-16 Universite Laval Nicotinic receptor agonists for the treatment of inflammatory diseases
CA2341952A1 (fr) 2001-03-23 2002-09-23 Universite Laval Agonistes du recepteur de la nicotine pour le traitement des maladies pulmonaires inflammatoires
WO2002094321A1 (fr) 2001-05-23 2002-11-28 Tanabe Seiyaku Co., Ltd. Compositions favorisant la guérison d'une fracture osseuse
JP4510383B2 (ja) 2001-05-23 2010-07-21 田辺三菱製薬株式会社 軟骨疾患修復治療用組成物
DK3384931T3 (da) * 2002-03-01 2019-09-16 Chiesi Farm Spa Superfin formoterolformulering
US8557804B2 (en) 2002-03-25 2013-10-15 Universite Laval Nicotinic receptor agonists for the treatment of inflammatory diseases
US8039459B2 (en) 2004-07-15 2011-10-18 Universite Laval Nicotinic receptor agonists for the treatment of inflammatory diseases
US20040121003A1 (en) * 2002-12-19 2004-06-24 Acusphere, Inc. Methods for making pharmaceutical formulations comprising deagglomerated microparticles
US7419801B2 (en) * 2003-08-08 2008-09-02 Arriva Pharmaceuticals, Inc. Methods of protein production in yeast
GB0327723D0 (en) * 2003-09-15 2003-12-31 Vectura Ltd Pharmaceutical compositions
DK1684719T3 (da) * 2003-11-14 2012-01-30 Baxter Int Alfa-1-antitrypsin-sammensætninger og behandlingsfremgangsmåder, der anvender sådanne sammensætninger
CA2550841C (fr) 2004-02-06 2012-10-02 Meda Pharma Gmbh & Co. Kg Nouvelle combinaison d'anticholinergique et de beta-mimetiques pour le traitement de maladies respiratoires
WO2005074983A2 (fr) * 2004-02-06 2005-08-18 Meda Pharma Gmbh & Co. Kg Traitement de la rhinite avec des anticholinergiques seuls ou combines a des antihistaminiques, des inhibiteurs de phosphodiesterase 4, ou des corticosteroides
HRP20120286T1 (hr) * 2004-02-06 2012-04-30 Meda Pharma Gmbh & Co. Kg Kombinacija antikolinergika i inhibitora fosfodiesteraze tip 4 za liječenje respiratornih bolesti
PL1713473T3 (pl) * 2004-02-06 2013-08-30 Meda Pharma Gmbh & Co Kg Kombinacja leków antycholinergicznych i glikokortykoidów do długotrwałego leczenia astmy i POChP
JP2007524698A (ja) * 2004-02-27 2007-08-30 アルタナ　ファルマ　アクチエンゲゼルシャフト シクレソニドとグリコピロニウムとの組合せ物
CA2559062A1 (fr) * 2004-03-09 2005-09-22 Arriva Pharmaceuticals, Inc. Traitement de la bronchopneumopathie chronique obstructive par inhalation a faible dose d'inhibiteur de protease
GB0409703D0 (en) 2004-04-30 2004-06-02 Vectura Ltd Pharmaceutical compositions
GB0410399D0 (en) * 2004-05-10 2004-06-16 Arakis Ltd The treatment of respiratory disease
GB0410398D0 (en) * 2004-05-10 2004-06-16 Arakis Ltd The treatment of respiratory disease
GB0411056D0 (en) 2004-05-18 2004-06-23 Novartis Ag Organic compounds
WO2006003078A1 (fr) * 2004-06-29 2006-01-12 Boehringer Ingelheim International Gmbh Medicaments pour inhalation comprenant des steroides et un anticholinergique
EP1616567A1 (fr) * 2004-07-16 2006-01-18 Boehringer Ingelheim Pharma GmbH & Co.KG Médicaments comprenant des inhibiteurs de PDE-IV et des sels de glycopyrolate pour l'inhalation
EP1789018A1 (fr) 2004-08-27 2007-05-30 The Dow Chemical Company Administration amelioree de compositions medicamenteuses pour le traitement d'infections parfois mortelles
US20070105768A1 (en) * 2004-11-10 2007-05-10 Rajiv Nayar Dry recombinant human alpha 1-antitrypsin formulation
GB0425758D0 (en) 2004-11-23 2004-12-22 Vectura Ltd Preparation of pharmaceutical compositions
WO2006087919A1 (fr) * 2005-01-28 2006-08-24 Takeda Pharmaceutical Company Limited Composition finement divisee contenant un substance peu hydrosoluble
JP4991693B2 (ja) 2005-03-16 2012-08-01 メダ ファーマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト 呼吸器疾患の治療のための抗コリン作用薬及びロイコトリエン受容体アンタゴニストの組み合わせ剤
US7915303B2 (en) * 2005-03-24 2011-03-29 Sosei R&D Ltd. Glycopyrronium salts and their therapeutic use
EP1978933A2 (fr) * 2005-12-15 2008-10-15 Acusphere, Inc. Procédés de préparation de formulations pharmaceutiques à base de particules destinées à une administration orale
NZ568349A (en) 2005-12-21 2011-05-27 Meda Pharma Gmbh & Co Kg Combination of anticholinergics, glucocorticoids, beta2-agonists, PDE 4 inhibitor and antileukotriene for the treatment of inflammatory diseases
GB2434098A (en) * 2005-12-23 2007-07-18 Novartis Ag Process for the preparation of an inhalable dry powder formulation
WO2007109142A2 (fr) * 2006-03-17 2007-09-27 Oregon Health & Science University Antagonistes du recepteur muscarinique m3 pour le traitement des tumeurs exprimant le recepteur muscarinique m3
GB0613161D0 (en) 2006-06-30 2006-08-09 Novartis Ag Organic Compounds
CN101896162B (zh) * 2007-12-13 2013-06-05 诺瓦提斯公司 有机化合物
JP2011506400A (ja) * 2007-12-13 2011-03-03 ノバルティス アーゲー 有機化合物
US20100055045A1 (en) 2008-02-26 2010-03-04 William Gerhart Method and system for the treatment of chronic obstructive pulmonary disease with nebulized anticholinergic administrations
WO2009134524A2 (fr) * 2008-02-26 2009-11-05 Elevation Pharmaceuticals, Inc. Procédé et système permettant de traiter la bronchopneumopathie chronique obstructive au moyen d'administrations d'anticholinergiques par nébulisation
LT3578169T (lt) 2009-02-26 2024-08-26 Glaxo Group Limited Farmaciniai preparatai, apimantys 4-{(1r)-2-[(6-{2-[(2,6-dichlorbenzil) oksi]etoksi}heksil)amino]-1-hidroksietil}-2-(hidroksimetil)fenolį
US8815258B2 (en) 2009-05-29 2014-08-26 Pearl Therapeutics, Inc. Compositions, methods and systems for respiratory delivery of two or more active agents
EP3111926B1 (fr) 2009-05-29 2019-12-11 Pearl Therapeutics, Inc. Compositions, procédés et systèmes pour une administration respiratoire de deux ou de plusieurs agents actifs
GB0921075D0 (en) 2009-12-01 2010-01-13 Glaxo Group Ltd Novel combination of the therapeutic agents
UA106098C2 (uk) 2009-12-23 2014-07-25 К'Єзі Фармачеутічі С.П.А. Аерозольна композиція для хозл
CN102695496B (zh) 2009-12-23 2014-10-01 奇斯药制品公司 用于copd的气雾剂制剂
CA2785321C (fr) 2009-12-23 2018-08-21 Chiesi Farmaceutici S.P.A. Polytherapie pour bronchopneumopathie chronique obstructive (copd)
BR112012015334A2 (pt) 2009-12-23 2016-03-15 Chiesi Farma Spa terapia combinada para doença pulmonar obstrutiva crônica
WO2012044736A1 (fr) * 2010-09-29 2012-04-05 Pulmatrix, Inc. Poudres sèches à cations métalliques monovalents pour inhalation
JOP20120023B1 (ar) 2011-02-04 2022-03-14 Novartis Ag صياغات مساحيق جافة من جسيمات تحتوي على واحد أو اثنين من المواد الفعالة لعلاج امراض ممرات الهواء الانسدادية او الالتهابية
ES2708218T3 (es) 2011-08-01 2019-04-09 Univ Monash Método y formulación para inhalación
CA2865972C (fr) 2012-02-29 2022-01-04 Pulmatrix, Inc. Poudres seches pouvant etre inhalees
RU2696582C2 (ru) 2013-03-15 2019-08-05 Перл Терапьютикс, Инк. Способы и системы кондиционирования дисперсных кристаллических материалов
WO2014165303A1 (fr) 2013-04-01 2014-10-09 Pulmatrix, Inc. Poudres sèches de tiotropium
US9393202B2 (en) * 2013-04-26 2016-07-19 Chiesi Farmaceutici S.P.A Particle size reduction of an antimuscarinic compound
WO2015094927A1 (fr) * 2013-12-17 2015-06-25 Merck Sharp & Dohme Corp. Procédé de broyage de milieux pour la fabrication de composants pharmaceutiques actifs dans des propulseurs
HUE039513T2 (hu) 2013-12-30 2019-01-28 Chiesi Farm Spa Glikopirrónium-bromid és formoterol kombinációját tartalmazó nyomás alatti stabil aeroszol oldatkészítmény
NZ728435A (en) 2014-09-09 2017-11-24 Vectura Ltd Formulation comprising glycopyrrolate, method and apparatus
EP3332767B1 (fr) * 2014-09-15 2019-03-20 Verona Pharma PLC Formulation d'inhalation liquide comprenant rpl554
MA41378A (fr) * 2015-01-20 2017-11-28 Teva Branded Pharmaceutical Prod R & D Inc Inhalateur de poudre sèche comprenant du propionate de fluticasone et du xinafoate de salmétérol
US20160310410A1 (en) 2015-04-24 2016-10-27 Glenmark Specialty S.A. Pharmaceutical compositions comprising arformoterol and glycopyrronium
AU2016279798B2 (en) * 2015-06-15 2021-07-08 Qaam Pharmaceuticals, Llc Glycopyrronium fatty acid salts and methods of making same
US9925168B2 (en) * 2016-01-22 2018-03-27 Chiesi Farmaceutici S.P.A. Preparation of micronized particles of an antimuscarinic compound by hydrodynamic cavitation
US10098837B2 (en) 2016-07-28 2018-10-16 Chiesi Farmaceutici S.P.A. Combination therapy for COPD
PE20221439A1 (es) 2019-12-02 2022-09-21 Chiesi Farm Spa Lata de acero inoxidable para inhaladores dosificadores presurizados

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3400197A (en) 1965-01-26 1968-09-03 Robins Co Inc A H Compressible sustained release pharmaceutical tablet lipid-colloidal silica gel matrix fragment granules
US5376386A (en) * 1990-01-24 1994-12-27 British Technology Group Limited Aerosol carriers
US5849263A (en) * 1993-03-30 1998-12-15 Charlotte-Mecklenburg Hospital Authority Pharmaceutical compositions containing alkylaryl polyether alcohol polymer
TW402506B (en) * 1993-06-24 2000-08-21 Astra Ab Therapeutic preparation for inhalation
DE4425255A1 (de) * 1994-07-16 1996-01-18 Asta Medica Ag Formulierung zur inhalativen Applikation
AR002009A1 (es) * 1994-12-22 1998-01-07 Astra Ab Composicion farmaceutica, procedimiento para la manufactura de un polvo de proliposoma como el utilizado en dicha composicion, procedimiento para lamanufactura de dicha composicion, uso de dicha composicion farmaceutica en la manufactura de un medicamento y dispositivo inhalador de polvo seco.
US5612053A (en) * 1995-04-07 1997-03-18 Edward Mendell Co., Inc. Controlled release insufflation carrier for medicaments
US5690374A (en) * 1996-04-19 1997-11-25 Nor-Easter Enterprises, Inc. Shock-absorbing tool handle
US6613795B2 (en) 1996-11-11 2003-09-02 Christian Noe Enantiomerically pure basic arylcycloalkylhydroxycarboxylic esters, processes for their preparation and their use in medicaments
PT1371645E (pt) 1996-11-11 2013-05-21 Meda Pharma Gmbh & Co Kg Utilização de (3s,2¿r)-glicopirrónio como produto farmacêutico
ATE287257T1 (de) * 1997-01-16 2005-02-15 Massachusetts Inst Technology Zubereitung von partikelhaltigen arzneimitteln zur inhalation
SE9700133D0 (sv) * 1997-01-20 1997-01-20 Astra Ab New formulation
WO1998034595A1 (fr) * 1997-02-05 1998-08-13 Jago Research Ag Formulations medicales pour aerosols
US6495167B2 (en) * 1997-03-20 2002-12-17 Schering Corporation Preparation of powder agglomerates
AU748867B2 (en) * 1998-07-24 2002-06-13 Jagotec Ag Medicinal aerosol formulations
CA2338680C (fr) * 1998-08-04 2008-10-14 Jago Research Ag Formulations d'aerosol a usage medical
EP1131059B1 (fr) * 1998-11-13 2003-03-05 Jago Research Ag Poudre seche pour inhalation
US6406745B1 (en) * 1999-06-07 2002-06-18 Nanosphere, Inc. Methods for coating particles and particles produced thereby
AU7389300A (en) * 1999-08-02 2001-02-19 First Horizon Pharmaceutical Corporation Methods of administration of glycopyrrolate compositions
GB0008660D0 (en) 2000-04-07 2000-05-31 Arakis Ltd The treatment of respiratory diseases
US6758795B2 (en) 2000-08-22 2004-07-06 Stephen Barber Adjustable water-fillable exercise weights
GB0029903D0 (en) * 2000-12-07 2001-01-24 Arakis Ltd Use of anti-muscarinic agents
GB0410399D0 (en) * 2004-05-10 2004-06-16 Arakis Ltd The treatment of respiratory disease
GB0410398D0 (en) * 2004-05-10 2004-06-16 Arakis Ltd The treatment of respiratory disease
TWI509631B (zh) 2011-02-25 2015-11-21 漢高智慧財產控股公司 用於電子裝置之可燒結銀薄片黏著劑

Also Published As

Publication number Publication date
EP1267866B1 (fr) 2006-06-21
AU776913B2 (en) 2004-09-23
CY1105120T1 (el) 2010-03-03
US8029768B2 (en) 2011-10-04
NZ535284A (en) 2006-04-28
US20030068280A1 (en) 2003-04-10
EP1267866A2 (fr) 2003-01-02
EP1449528A1 (fr) 2004-08-25
GB0008660D0 (en) 2000-05-31
US20050019271A1 (en) 2005-01-27
CN101181263A (zh) 2008-05-21
JP5042426B2 (ja) 2012-10-03
US7229607B2 (en) 2007-06-12
NO336142B1 (no) 2015-05-26
NZ521476A (en) 2004-10-29
NO2015024I1 (no) 2015-11-25
DK1267866T3 (da) 2006-10-23
AU2010200660B2 (en) 2012-04-19
JP2003530344A (ja) 2003-10-14
DE60120936T3 (de) 2016-11-17
CA2405705A1 (fr) 2001-10-18
WO2001076575A3 (fr) 2002-03-28
HU230958B1 (hu) 2019-06-28
DK1267866T4 (en) 2016-10-03
WO2001076575A2 (fr) 2001-10-18
US7368104B2 (en) 2008-05-06
HK1050846A1 (en) 2003-07-11
NO2015025I1 (no) 2015-12-07
AU8930601A (en) 2001-10-23
LU92393I2 (fr) 2015-11-02
DE60120936T2 (de) 2006-11-02
MXPA02009718A (es) 2003-05-27
ES2266242T5 (es) 2016-10-04
ES2687751T3 (es) 2018-10-29
BE2013C023I2 (fr) 2020-06-24
HUP0301518A2 (hu) 2003-08-28
PT1267866E (pt) 2006-10-31
ZA200207420B (en) 2003-09-16
HUS1900056I1 (hu) 2020-02-28
NO20024708D0 (no) 2002-10-01
NO20024708L (no) 2002-10-24
HK1050846B (en) 2007-01-26
CA2405705C (fr) 2011-06-07
IL151791A (en) 2015-05-31
NO2015024I2 (no) 2015-11-25
ES2266242T3 (es) 2007-03-01
EP2193791A1 (fr) 2010-06-09
AU2004242450A1 (en) 2005-01-20
EP1267866B2 (fr) 2016-07-20
CN1422154A (zh) 2003-06-04
BR0109875A (pt) 2004-07-20
CN1720995A (zh) 2006-01-18
PL364024A1 (en) 2004-11-29
CN1292745C (zh) 2007-01-03
IL151791A0 (en) 2003-04-10
US20080220073A1 (en) 2008-09-11
AU2010200660A1 (en) 2010-03-11
ATE330585T2 (de) 2006-07-15
AU2004242450B2 (en) 2010-06-03
EP1449528B1 (fr) 2018-08-08
DE60120936D1 (de) 2006-08-03
CN101181263B (zh) 2011-07-06

Similar Documents

Publication Publication Date Title
LU92166I2 (fr) Glycopyrronium ou un de ses sels
WO2002015662A3 (fr) Fractions heteroaryle substituees par quinuclidine destinees au traitement de maladies
WO2002017358A3 (fr) Fractions heteroaryle substituees par quinuclidine destinees au traitement de maladies
IL187438A0 (en) Pyrrolopyridine derivatives and pharmaceutical compositions containing the same
BR0212042A (pt) Composto, composição farmacêutica, método de tratamento ou prevenção de doenças, e, uso de um composto
WO2005032471A3 (fr) Inhibiteurs de type benzylether et benzylamino de beta-secretase pour le traitement de la maladie d'alzheimer
NO2014009I2 (no) Forbindelser, farmasøytiske sammensetninger og anvendelser derav, samt fremgangsmåte for å fremstille nevnte forbindelser
CY1111693T1 (el) Αντιιικοι παραγοντες
MY138252A (en) Azabicyclic-substitud fused-heteroaryl compounds for the treatment of disease
WO2002042462A3 (fr) Agents therapeutiques et methodes d'utilisation de ces agents therapeutiques pour traiter une maladie amyloidogenique
YU92501A (sh) Levodop/karbidop/entakapon farmaceutski preparat
MXPA02011311A (es) Composicion novedosa.
MY138797A (en) Bacterial gyrase inhibitors and uses thereof
BR0316350A (pt) Diaminotriazóis úteis como inibidores de proteìna cinases
DE60219954D1 (de) Neue Indol-2-on Derivate
CL2007000789A1 (es) Compuestos derivados de malonamida, inhibidores de la gamma-secretasa; proceso de preparacion; composicion farmaceutica; y su uso en el tratamiento de la enfermedad de alzheimer.
WO2005051914A8 (fr) Inhibiteurs de benzylether et benzylamino de beta-secretase pour traiter la maladie d'alzheimer
NO20081843L (no) Farmasoytisk sammensetning for forbedret kognitiv funksjon
ATE396174T1 (de) Hydroxyalkylaminderivate als beta-secretase- inhibitoren und deren verwendung zur behandlung der alzheimerschen krankheit oder ähnlicher krankheiten
IL188942A0 (en) Benzimidazole derivatives and pharmaceutical compositions containing the same
NO20060149L (no) Farmasoytiske forbindelser av atorvastatin
PT1223972E (pt) Suspensao de uma proteina de epi-hne processo para a sua preparacao aerossol de po anidro derivado dela composicoes farmaceuticas contendo a referida suspensao ou aerossol e as suas utilizacoes
WO2006057945A3 (fr) Derives pyridyle 2,3,4,6-substitues utiles comme inhibiteurs de la beta-secretase pour le traitement de la maladie d'alzheimer
BRPI0417946A (pt) composto, métodos para o tratamento ou a profilaxia de uma doença ou condição, e de distúrbios, e para a indução da cessação do hábito de fumar, composição farmacêutica, e, uso de um composto
CL2004000805A1 (es) Compuestos derivados de 7-aza-quinazolina sustituida, inhibidores de quinasa p38; procedimiento de preparacion; composicion farmaceutica; y su uso para tratar artritis, enfermedad de crohn, alzheimer, asma, ataque al corazon.